Katz J L, Alling K L
Psychobiology Section, NIDA Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
Behav Pharmacol. 2000 Sep;11(6):483-93. doi: 10.1097/00008877-200009000-00005.
Three separate groups of rats were trained to discriminate the putative D3 dopamine receptor agonists (+/-)-7-hydroxydipropylaminotetralin (7-OH-DPAT) (0.03 mg/kg), PD 128,907 (1.0 mg/kg) and quinpirole (0.03 mg/kg) from saline. Food was presented after each 10 (7-OH-DPAT and PD 128,907) or 20 (quinpirole) consecutive responses on one lever after administration of the training drug, and the other lever after the administration of saline. Once stable performances were obtained, the effects of various doses of several dopaminergic agonists were assessed during test sessions in which responses on either lever were reinforced. The substitution tests were conducted to determine if differences in potencies would be obtained, which would be suggestive of differences in the mechanisms underlying the discriminative effects of the training drugs. Non-selective agonists with activity at both D2 and D3 dopamine receptors (D2-like agonists) substituted for each of the three training drugs. In addition, the selective D2 dopamine receptor agonist U91356A also generalized to both 7-OH-DPAT and PD 128,907. The potencies of the D2-like agonists in substituting for each training drug were highly correlated with potencies in substituting for the others. SKF 82958 and SKF 81297, agonists with selectivity for D1 and D5 dopamine receptors (D1-like agonists), partially substituted for 7-OH-DPAT but not PD 128,907. The D1-like partial agonist SKF 38393 did not substitute for any of the training drugs for which it was tested. Cocaine produced intermediate substitution in 7-OH-DPAT- and PD 128,907-trained subjects and did not substitute at all in quinpirole-trained subjects. The dopamine D1-like antagonist SCH 39166 (0.001-0.03 mg/kg) did not alter the discriminative stimulus effects of PD 128,907, whereas the D2-like dopamine antagonist spiperone (0.001-0.1 mg/kg) produced at the highest dose an insurmountable antagonism of the discriminative effects of PD 128,907. In contrast, there was no appreciable antagonism of the effects of PD 128,907 on response rates. The data collected are consistent with a distinction between the effects of each of these training drugs and the indirectly acting agonist cocaine. Further, these data indicate that there are differences in the mechanisms underlying the discriminative effects of PD 128,907 and its effects on response rates. Moreover, these data indicate that each of the training drugs is distinct from drugs acting through D1 dopaminergic mechanisms. However, there were no data that clearly distinguished these training drugs from each other or from drugs acting through D2 dopaminergic mechanisms.
将三组大鼠分别训练,使其能够区分假定的D3多巴胺受体激动剂(±)-7-羟基二丙基氨基四氢萘(7-OH-DPAT)(0.03毫克/千克)、PD 128,907(1.0毫克/千克)和喹吡罗(0.03毫克/千克)与生理盐水。在给予训练药物后,每连续在一个杠杆上做出10次(7-OH-DPAT和PD 128,907)或20次(喹吡罗)反应后给予食物,给予生理盐水后则在另一个杠杆上做出反应后给予食物。一旦获得稳定的表现,就在测试阶段评估几种多巴胺能激动剂不同剂量的效果,在测试阶段,对任一杠杆的反应都会得到强化。进行替代试验以确定是否会获得效价差异,这将提示训练药物辨别效应背后机制的差异。对D2和D3多巴胺受体均有活性的非选择性激动剂(D2样激动剂)可替代三种训练药物中的每一种。此外,选择性D2多巴胺受体激动剂U91356A也能与7-OH-DPAT和PD 128,907产生交叉反应。D2样激动剂替代每种训练药物的效价与替代其他训练药物的效价高度相关。SKF 82958和SKF 81297是对D1和D5多巴胺受体有选择性的激动剂(D1样激动剂),可部分替代7-OH-DPAT,但不能替代PD 128,907。D1样部分激动剂SKF 38393不能替代所测试的任何一种训练药物。可卡因在7-OH-DPAT和PD 128,907训练的受试者中产生中等程度的替代作用,但在喹吡罗训练的受试者中根本不产生替代作用。多巴胺D1样拮抗剂SCH 39166(0.001 - 0.03毫克/千克)不会改变PD 128,907的辨别刺激效应,而D2样多巴胺拮抗剂螺哌隆(0.001 - 0.1毫克/千克)在最高剂量时对PD 128,907的辨别效应产生不可克服的拮抗作用。相比之下,PD 128,907对反应率的影响没有明显的拮抗作用。收集到的数据与这些训练药物中每种药物的效应以及间接作用激动剂可卡因的效应之间的差异一致。此外,这些数据表明,PD 128,907的辨别效应及其对反应率的影响背后的机制存在差异。而且,这些数据表明每种训练药物都与通过D1多巴胺能机制起作用的药物不同。然而,没有数据能明确区分这些训练药物彼此之间或与通过D2多巴胺能机制起作用的药物。